Benchmark Holdings
Ticker: BMK Exchange: AIM

Benchmark helps deliver improved healthcare products and welfare services to the global aquaculture and livestock industries. Rising demand from clients for its products and services to manage sustainability practice and performance underlines BMK's opportunity for significant organic and external growth.

EMA safety nod for game-changer BMK08

Benchmark has received a notification of positive safety opinion from the European Medicines Agency regarding BMK08, the Company’s revolutionary sea lice treatment, used in combination with the CleanTreat® purification system. This is a significant milestone and means that in the opinion of the EMA, the treatment is safe for consumers after extensive testing showing its compliance with the maximum residue limits (MRL).

The positive opinion paves the way for achieving regulatory clearance from the EU and is a condition of Marketing Approval for the novel treatment in the initial target market of Norway. The anticipated launch of CleanTreat® + BMK08 is therefore well on track for Q2 2021 (calendar year).

Download as a PDF file
26810392321 - benchmark-holdings
Return to Benchmark Holdings

Register for updates

Sign up to get access to our latest content as soon as it’s published

Register For Updates